News & Videos - AMGEN INC AMGEN ORD (CDI)

AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., June 5, 2024 THOUSAND OAKS, Calif. , June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45 th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday , June 10, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Jay Bradner , executive vice president of Research and Development and chief scientific officer at...

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) PR Newswire THOUSAND OAKS, Calif., June 5, 2024 Data Show a Statistically Significant 87% Reduction in IgG4-RD Flares, With Primary and All Key Secondary Endpoints Met First Randomized, Placebo-Controlled Trial to Demonstrate Benefit in IgG4-RD THOUSAND OAKS, Calif. , June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., June 3, 2024 THOUSAND OAKS, Calif. , June 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday , June 6, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Ian Thompson , senior vice president, U.S. Business Operations at Amgen, will present at the conference. The webcast will be broadcast...

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024 PR Newswire THOUSAND OAKS, Calif., May 28, 2024 Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) in Metastatic Colorectal Cancer Accepted as Late-Breaking Oral Presentation THOUSAND OAKS, Calif. , May 28, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024 PR Newswire THOUSAND OAKS, Calif., May 15, 2024 THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday , May 20, 2024 following the presentation of new data from TEZSPIRE ® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an...

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., May 9, 2024 THOUSAND OAKS, Calif. , May 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday , May 14, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Jay Bradner , executive vice president of Research and Development and chief scientific...

AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., May 2, 2024 THOUSAND OAKS, Calif. , May 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines advancing through our pipeline, we are excited about delivering attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include:...

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 PR Newswire THOUSAND OAKS, Calif., May 1, 2024 Findings From Tezspire ® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS ® (avacopan) Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement THOUSAND OAKS, Calif. , May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new...

AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., April 29, 2024 THOUSAND OAKS, Calif. , April 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A....

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY PR Newswire THOUSAND OAKS, Calif., April 26, 2024 THOUSAND OAKS, Calif. , April 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of...

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024 PR Newswire THOUSAND OAKS, Calif., April 16, 2024 Planning Underway for Phase 3 Development of Tezepelumab in COPD THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND PR Newswire THOUSAND OAKS, Calif., March 6, 2024 THOUSAND OAKS, Calif. , March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024 , to all stockholders of record as of the close of business on May 17, 2024 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from...

AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Feb. 29, 2024 THOUSAND OAKS, Calif. , Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday , March 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Paul Burton , senior vice president and chief medical officer at Amgen, will present at the conference. The webcast...

AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO PR Newswire THOUSAND OAKS, Calif., Feb. 26, 2024 THOUSAND OAKS, Calif. , Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio , the newest in its global operations network and the most advanced facility to date. "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient,...

AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE PR Newswire THOUSAND OAKS, Calif., Feb. 19, 2024 THOUSAND OAKS, Calif. , Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon , executive vice president of Global Commercial Operations at...

AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE PR Newswire THOUSAND OAKS, Calif., Feb. 9, 2024 THOUSAND OAKS, Calif. , Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34 th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday , Feb. 14, 2024. Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon , executive vice president of Global Commerical...

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Feb. 6, 2024 THOUSAND OAKS, Calif. , Feb. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. "2023 was another year of performance and progress for our company," said Robert A. Bradway , chairman and chief executive officer. "Our marketed products are reaching many more patients around the...

AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Feb. 1, 2024 THOUSAND OAKS, Calif. , Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call...

AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Jan. 3, 2024 THOUSAND OAKS, Calif. , Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news...

AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB) PR Newswire THOUSAND OAKS, Calif., Dec. 26, 2023 FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif. , Dec. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application...